Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.